176 related articles for article (PubMed ID: 18189332)
21. Ambivalent role of BCL6 in cell survival and transformation.
Albagli-Curiel O
Oncogene; 2003 Jan; 22(4):507-16. PubMed ID: 12555064
[TBL] [Abstract][Full Text] [Related]
22. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
23. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
[TBL] [Abstract][Full Text] [Related]
24. Roles of BCL6 in normal and transformed germinal center B cells.
Basso K; Dalla-Favera R
Immunol Rev; 2012 May; 247(1):172-83. PubMed ID: 22500840
[TBL] [Abstract][Full Text] [Related]
25. The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation.
Jaye DL; Iqbal J; Fujita N; Geigerman CM; Li S; Karanam S; Fu K; Weisenburger DD; Chan WC; Moreno CS; Wade PA
J Pathol; 2007 Sep; 213(1):106-15. PubMed ID: 17573669
[TBL] [Abstract][Full Text] [Related]
26. Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines.
Hollmann A; Aloyz R; Baker K; Dirnhofer S; Owens T; Sladek R; Tzankov A
Hematol Oncol; 2010 Sep; 28(3):142-50. PubMed ID: 20155735
[TBL] [Abstract][Full Text] [Related]
27. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
28. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
29. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.
Saito M; Gao J; Basso K; Kitagawa Y; Smith PM; Bhagat G; Pernis A; Pasqualucci L; Dalla-Favera R
Cancer Cell; 2007 Sep; 12(3):280-92. PubMed ID: 17785208
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the prognostic significance of BCL6 gene expression in canine high-grade B-cell lymphoma.
Sato M; Kanemoto H; Kagawa Y; Kobayashi T; Goto-Koshino Y; Mochizuki H; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2012 Jan; 191(1):108-14. PubMed ID: 21277811
[TBL] [Abstract][Full Text] [Related]
31. Kaiso is a key regulator of spleen germinal center formation by repressing Bcl6 expression in splenocytes.
Koh DI; Yoon JH; Kim MK; An H; Kim MY; Hur MW
Biochem Biophys Res Commun; 2013 Dec; 442(3-4):177-82. PubMed ID: 24269670
[TBL] [Abstract][Full Text] [Related]
32. Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6.
Ochiai K; Muto A; Tanaka H; Takahashi S; Igarashi K
Int Immunol; 2008 Mar; 20(3):453-60. PubMed ID: 18256039
[TBL] [Abstract][Full Text] [Related]
33. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
34. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
[TBL] [Abstract][Full Text] [Related]
35. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
[TBL] [Abstract][Full Text] [Related]
36. Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene.
Lima FP; Bousquet M; Gomez-Brouchet A; de Paiva GR; Amstalden EM; Soares FA; Dastugue N; Vassallo J; Brousset P
Am J Clin Pathol; 2008 May; 129(5):723-6. PubMed ID: 18426731
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
[TBL] [Abstract][Full Text] [Related]
38. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
[TBL] [Abstract][Full Text] [Related]
39. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
O'Connor OA; Hamlin P
Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
[TBL] [Abstract][Full Text] [Related]
40. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
Feuerhake F; Kutok JL; Monti S; Chen W; LaCasce AS; Cattoretti G; Kurtin P; Pinkus GS; de Leval L; Harris NL; Savage KJ; Neuberg D; Habermann TM; Dalla-Favera R; Golub TR; Aster JC; Shipp MA
Blood; 2005 Aug; 106(4):1392-9. PubMed ID: 15870177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
